These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1421 related items for PubMed ID: 15766996

  • 1. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
    Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, Tolosa E, LARGO study group.
    Lancet; ; 365(9463):947-54. PubMed ID: 15766996
    [Abstract] [Full Text] [Related]

  • 2. Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease.
    Stocchi F, Rabey JM.
    Eur J Neurol; 2011 Dec; 18(12):1373-8. PubMed ID: 21895884
    [Abstract] [Full Text] [Related]

  • 3. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
    Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P, Bi-Park 1 investigators.
    Lancet Neurol; 2016 Feb; 15(2):154-165. PubMed ID: 26725544
    [Abstract] [Full Text] [Related]

  • 4. Rasagiline for motor complications in Parkinson's disease.
    Clarke CE.
    Lancet; 2016 Feb; 365(9463):914-6. PubMed ID: 15766976
    [No Abstract] [Full Text] [Related]

  • 5. Rasagiline adjunct therapy in patients with Parkinson's disease: post hoc analyses of the PRESTO and LARGO trials.
    Elmer LW.
    Parkinsonism Relat Disord; 2013 Nov; 19(11):930-6. PubMed ID: 23849501
    [Abstract] [Full Text] [Related]

  • 6. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
    Parkinson Study Group.
    Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
    [Abstract] [Full Text] [Related]

  • 7. Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease.
    Tolosa E, Stern MB.
    Eur J Neurol; 2012 Feb; 19(2):258-64. PubMed ID: 21819487
    [Abstract] [Full Text] [Related]

  • 8. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study.
    Brooks DJ, Sagar H, UK-Irish Entacapone Study Group.
    J Neurol Neurosurg Psychiatry; 2003 Aug; 74(8):1071-9. PubMed ID: 12876237
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of adjunctive rasagiline in Japanese Parkinson's disease patients with wearing-off phenomena: A phase 2/3, randomized, double-blind, placebo-controlled, multicenter study.
    Hattori N, Takeda A, Takeda S, Nishimura A, Kato M, Mochizuki H, Nagai M, Takahashi R.
    Parkinsonism Relat Disord; 2018 Aug; 53():21-27. PubMed ID: 29748109
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations.
    Reichmann H, Boas J, Macmahon D, Myllyla V, Hakala A, Reinikainen K, ComQol Study Group.
    Acta Neurol Scand; 2005 Jan; 111(1):21-8. PubMed ID: 15595934
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study.
    Durif F, Devaux I, Pere JJ, Delumeau JC, Bourdeix I, F-01 Study Group.
    Eur Neurol; 2001 Jan; 45(2):111-8. PubMed ID: 11244274
    [Abstract] [Full Text] [Related]

  • 12. Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline.
    deMarcaida JA, Schwid SR, White WB, Blindauer K, Fahn S, Kieburtz K, Stern M, Shoulson I, Parkinson Study Group TEMPO, PRESTO Tyramine Substudy Investigators and Coordinators.
    Mov Disord; 2006 Oct; 21(10):1716-21. PubMed ID: 16856145
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).
    Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M, Celomen Study Group.
    Acta Neurol Scand; 2002 Apr; 105(4):245-55. PubMed ID: 11939936
    [Abstract] [Full Text] [Related]

  • 14. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
    Fung VS, Herawati L, Wan Y, Movement Disorder Society of Australia Clinical Research and Trials Group, QUEST-AP Study Group.
    Mov Disord; 2009 Jan 15; 24(1):25-31. PubMed ID: 18846551
    [Abstract] [Full Text] [Related]

  • 15. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ, Swope DM, Dashtipour K.
    Clin Ther; 2007 Sep 15; 29(9):1825-49. PubMed ID: 18035186
    [Abstract] [Full Text] [Related]

  • 16. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Parkinson Study Group.
    Ann Neurol; 1997 Nov 15; 42(5):747-55. PubMed ID: 9392574
    [Abstract] [Full Text] [Related]

  • 17. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J, Kaakkola S, Ahtila S, Tuomainen P, Teräväinen H.
    Mov Disord; 1997 Jul 15; 12(4):497-505. PubMed ID: 9251066
    [Abstract] [Full Text] [Related]

  • 18. Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study.
    Zijlmans JC, Debilly B, Rascol O, Lees AJ, Durif F.
    Mov Disord; 2004 Sep 15; 19(9):1006-1011. PubMed ID: 15372589
    [Abstract] [Full Text] [Related]

  • 19. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH, Klasser M, Reichmann H.
    Fortschr Neurol Psychiatr; 2008 Oct 15; 76(10):594-9. PubMed ID: 18833504
    [Abstract] [Full Text] [Related]

  • 20. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.
    Rascol O, Fitzer-Attas CJ, Hauser R, Jankovic J, Lang A, Langston JW, Melamed E, Poewe W, Stocchi F, Tolosa E, Eyal E, Weiss YM, Olanow CW.
    Lancet Neurol; 2011 May 15; 10(5):415-23. PubMed ID: 21482191
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 72.